Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in MDS
NCT01111448Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Technische Universität Dresden. Primary endpoint: Overall hematological response rate at 4 months. Started Apr 2010; status: terminated.
02
Drugs
temsirolimus
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01111448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111448.